Lilly claims partial victory for Alzheimer's drug

Top-line results show some hope for treatment even though a research goal was missed.

By Minyanville.com Aug 24, 2012 12:48PM
Image: Insurance Money (© Comstock Images/Jupiterimages)Shares of Eli Lilly (LLY) are rising on hope for the company's experimental treatment for Alzheimer's disease. 

As expected, Lilly said the drug didn't meet primary goals in a late-stage human trial. However, Lilly said the drug, solanezumab, did show some promise and the company plans to continue studying it. 

The news was a surprise as many investors had given up on the drug. The initial study data suggested the medicine slowed the cognitive decline -- which usually means things like memory loss -- in patients with mild to moderate Alzheimer's, but did not   improve mental ability.

"We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive decline," said John C. Lechleiter, chief executive officer of Lilly. "We intend to discuss these data with regulatory authorities to gain their insights on potential next steps."

Shares of Lilly jumped 4% to $44 in trading Friday morning, though the gains were pared to 2.55% around noon. 

However, some analysts cautioned that the drug still has a way to go before being approved.

"Basically the odds of approval just went up from (about) 10% to maybe 20 to 30%," ISI Group analyst Mark Schoenebaum says. He calls chances for the drug's success "still high risk" but notes the study results are much better than expected.

The data will be very controversial, he adds. Had the drug been shown to clearly meet its study goals, Lilly's stock might have jumped 50%, the analyst says. On the other hand, the stock was expected to drop on failure, even though expectations for a positive result were low.

Sentiment toward Lilly's drug soured after a similar treatment being developed by Pfizer (PFE), Johnson & Johnson (JNJ) and Elan (ELN) failed in studies. The disappointing results prompted those companies to pull the plug on their clinical program earlier this month.  

Like other big drug companies, Lilly needs to replace sales of big products that have lost or are losing patent protection, opening them to generic competition.

More from Minyanville


0Comments

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

116
116 rated 1
284
284 rated 2
461
461 rated 3
671
671 rated 4
628
628 rated 5
618
618 rated 6
615
615 rated 7
495
495 rated 8
347
347 rated 9
115
115 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
DYNDYNEGY Inc10
TAT&T Inc9
VZVERIZON COMMUNICATIONS9
EXCEXELON CORPORATION8
AAPLAPPLE Inc10
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.